advertisement
11.14 Investigational drugs; pharmacological experiments (62)
Showing records 1 to 25
Display all abstracts in classification 11.14 Investigational drugs; pharmacological experiments
Search within classification 11.14 Investigational drugs; pharmacological experiments90747 Tissue plasminogen activator attenuates outflow facility reduction in mouse model of juvenile open angle glaucoma
Gindina S
Experimental Eye Research 2020; 199: 108179
90210 Omidenepag Isopropyl Versus Latanoprost in Primary Open-Angle Glaucoma and Ocular Hypertension: The Phase 3 AYAME Study
Aihara M
American Journal of Ophthalmology 2020; 220: 53-63
89941 Current and new pharmacotherapeutic approaches for glaucoma
Shalaby WS
Expert Opinion in Pharmacotherapy 2020; 21: 2027-2040
90309 Effect of palmitoylethanolamide on inner retinal function in glaucoma: a randomized, single blind, crossover, clinical trial by pattern-electroretinogram
Rossi GCM
Scientific reports 2020; 10: 10468
89941 Current and new pharmacotherapeutic approaches for glaucoma
Shalaby WS
Expert Opinion in Pharmacotherapy 2020; 21: 2027-2040
90673 AR12286 Alleviates TGF-β-Related Myofibroblast Transdifferentiation and Reduces Fibrosis after Glaucoma Filtration Surgery
Cheng WS
Molecules 2020; 25:
89975 A comprehensive map of disease networks and molecular drug discoveries for glaucoma
Wang H
Scientific reports 2020; 10: 9719
90564 Intraocular pressure-lowering effect of omidenepag isopropyl in latanoprost non-/low-responder patients with primary open-angle glaucoma or ocular hypertension: the FUJI study
Aihara M
Japanese Journal of Ophthalmology 2020; 64: 398-406
89941 Current and new pharmacotherapeutic approaches for glaucoma
Shalaby WS
Expert Opinion in Pharmacotherapy 2020; 21: 2027-2040
90736 New antiglaucomatous agent for the treatment of open angle glaucoma: Polymeric inserts for drug release and in vitro and in vivo study
Cesar ALA
Journal of Biomedical Materials Research - Part A 2021; 109: 336-345
90166 Can Treatment With Citicoline Eyedrops Reduce Progression in Glaucoma? The Results of a Randomized Placebo-controlled Clinical Trial
Rossetti L
Journal of Glaucoma 2020; 29: 513-520
90673 AR12286 Alleviates TGF-β-Related Myofibroblast Transdifferentiation and Reduces Fibrosis after Glaucoma Filtration Surgery
Chen CL
Molecules 2020; 25:
90166 Can Treatment With Citicoline Eyedrops Reduce Progression in Glaucoma? The Results of a Randomized Placebo-controlled Clinical Trial
Iester M
Journal of Glaucoma 2020; 29: 513-520
90747 Tissue plasminogen activator attenuates outflow facility reduction in mouse model of juvenile open angle glaucoma
Hu Y
Experimental Eye Research 2020; 199: 108179
90309 Effect of palmitoylethanolamide on inner retinal function in glaucoma: a randomized, single blind, crossover, clinical trial by pattern-electroretinogram
Scudeller L
Scientific reports 2020; 10: 10468
90564 Intraocular pressure-lowering effect of omidenepag isopropyl in latanoprost non-/low-responder patients with primary open-angle glaucoma or ocular hypertension: the FUJI study
Ropo A
Japanese Journal of Ophthalmology 2020; 64: 398-406
89975 A comprehensive map of disease networks and molecular drug discoveries for glaucoma
Deng Y
Scientific reports 2020; 10: 9719
89941 Current and new pharmacotherapeutic approaches for glaucoma
Shankar V
Expert Opinion in Pharmacotherapy 2020; 21: 2027-2040
90210 Omidenepag Isopropyl Versus Latanoprost in Primary Open-Angle Glaucoma and Ocular Hypertension: The Phase 3 AYAME Study
Lu F
American Journal of Ophthalmology 2020; 220: 53-63
90736 New antiglaucomatous agent for the treatment of open angle glaucoma: Polymeric inserts for drug release and in vitro and in vivo study
Navarro LC
Journal of Biomedical Materials Research - Part A 2021; 109: 336-345
89941 Current and new pharmacotherapeutic approaches for glaucoma
Razeghinejad R
Expert Opinion in Pharmacotherapy 2020; 21: 2027-2040
90564 Intraocular pressure-lowering effect of omidenepag isopropyl in latanoprost non-/low-responder patients with primary open-angle glaucoma or ocular hypertension: the FUJI study
Lu F
Japanese Journal of Ophthalmology 2020; 64: 398-406
90736 New antiglaucomatous agent for the treatment of open angle glaucoma: Polymeric inserts for drug release and in vitro and in vivo study
Castilho RO
Journal of Biomedical Materials Research - Part A 2021; 109: 336-345
90166 Can Treatment With Citicoline Eyedrops Reduce Progression in Glaucoma? The Results of a Randomized Placebo-controlled Clinical Trial
Tranchina L
Journal of Glaucoma 2020; 29: 513-520
90747 Tissue plasminogen activator attenuates outflow facility reduction in mouse model of juvenile open angle glaucoma
Barron AO
Experimental Eye Research 2020; 199: 108179
